ArticleInfectious diseases and therapy2025
Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStreptococcus pneumoniae can cause serious invasive pneumococcal disease (IPD), such as pneumonia, meningitis and bactaeremia. Two pneumococcal polysaccharide conjugate vaccines (PCV), the 13-valent PCV13 and 10-valent PHiD-CV, are included in the Philippines' National Formulary and implemented in the national immunisation programme. Recently, a new 10-valent PCV (PCV10-SII) has received World Health Organization prequalification status. The objective of this study was to assess cost-effectiveness of the two 10-valent PCVs versus no vaccination and the relative cost-effectiveness of the two vaccines.
methodsAn existing Markov model was adapted to the Philippines context. Health outcomes, including bacteraemia, meningitis, pneumonia, acute otitis media (AOM), sequelae and death, were evaluated over a 5-year horizon without discounting. Quality-adjusted life years (QALYs) and costs were calculated over a lifetime horizon, applying a discount rate of 3.66%. The price of PCV10-SII was assumed to be 20% below the PHiD-CV market price; this price reduction was varied between 5% and 15% in scenario analyses.
resultsBoth vaccination strategies dominated the 'no vaccination' strategy, producing more health benefits at lower total costs. The incremental cost-effectiveness ratio of PHiD-CV versus PCV10-SII was 54,553 Philippine pesos (PHPs) per QALY gained in the base case analysis. Vaccination with PHiD-CV was predicted to yield more QALYs compared with PCV10-SII (ΔQALY: 2929) since more cases of meningitis, bactaeremia and AOM were prevented but at higher direct costs due to the vaccine price difference. PHiD-CV would be the dominant option if the price reduction for PCV10-SII was at most 5%.
conclusionsBoth vaccination strategies are superior to no vaccination, producing more health benefits at lower costs. QALYs gained are higher with PHiD-CV but at higher direct costs. Results are most sensitive to assumptions about PCV10-SII vaccine price.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.